Liminatus Pharma, Inc. · NASDAQ:LIMN

Liminatus Pharma, Inc. financial statements

Liminatus Pharma, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue0000
Research and development02.69M3.76M1.85M3.80M
Selling, general and administrative2.97M645.0K1.06M856.0K197.0K
Operating income-2.97M-3.33M-2.59M-2.71M-2.53M
Depreciation and amortization1.83K01.00K
EBITDA-2.97M-3.33M-2.71M
Interest expense215.9K338.9K175.0K219.0K
Income before tax-10.2M-2.89M-1.19M-2.93M4.37M
Income tax18.8K34.0K539.8K
Net income-10.2M-3.55M-1.23M-2.93M4.37M
Earnings per share, basic-0.43-0.20-7.65-4.256.33
Earnings per share, diluted-0.43-0.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents337.7K56.3K434.0K5.05M336.2K
Receivables6.46K945.0K100.0K1.26K
Current assets500.6K5.28M210.9K360.6K421.9K
Property, plant and equipment12.2K941
Total assets512.8K5.41M4.50M15.5M276.4M
Accounts payable582.2K1.48M933.0K508.0K419.0K
Current liabilities10.3M24.7M5.16M3.59M1.38M
Total debt1.44M5.12M16.1M16.5M90.0K
Total liabilities10.3M24.7M15.2M14.2M21.6M
Shareholders' equity-9.81M-19.3M-10.7M1.29M254.9M
Shares outstanding27.1M17.5M160.3K688.6K690.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-9.96M-1.45M-3.35M-869.0K-1.22M
Capital spending-13.1K0000
Free cash flow-9.98M-3.11M-3.35M-869.0K-1.22M
Cash from investing-788.1K-2.85M-819.0K264.0M-276.0M
Cash from financing11.0M3.92M-450.0K5.92M277.6M
Share buybacks-1.80M-10.7M-700.0K
Change in cash281.3K-378.1K-4.61M5.05M336.2K